Release Date: March 17, 2025
Expiration Date: March 17, 2026
Activity Overview
Care of patients with chronic lymphocytic leukemia (CLL), the most common hematologic leukemia among adults worldwide, has rapidly evolved away from chemoimmunotherapy to therapy that disrupts B-cell receptor signaling, including inhibitors of Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2). Clinical trials continue to optimize these treatments in order to maximize efficacy, minimize toxicity, and address areas of unmet need.
This webcast is designed to rapidly disseminate new clinically relevant data with appropriate context. Expert faculty focus on best practices and active areas of debate across the disease continuum.
This educational activity is an archive of the live virtual symposium held on February 20, 2025.
Target Audience
This educational activity is directed toward medical oncologists, hematologists/oncologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of CLL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the role of risk stratification, measurable residual disease (MRD) assessment, and resistance mechanisms in treatment selection and personalization for patients with CLL across multiple therapy lines.
- Analyze trial results from studies that evaluated BCL-2 inhibitor–based strategies in patients with CLL across all therapy lines.
- Devise effective strategies to monitor and mitigate treatment-related toxicities in patients with CLL.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
